Jay Schachner

568 total citations
10 papers, 459 citations indexed

About

Jay Schachner is a scholar working on Genetics, Hematology and Immunology. According to data from OpenAlex, Jay Schachner has authored 10 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Hematology and 5 papers in Immunology. Recurrent topics in Jay Schachner's work include Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Acute Myeloid Leukemia Research (3 papers). Jay Schachner is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Acute Myeloid Leukemia Research (3 papers). Jay Schachner collaborates with scholars based in United States. Jay Schachner's co-authors include Michael J. Keating, Emil J. Freireich, Charles Koller, Craig C. Childs, Moshe Talpaz, K. B. McCredie, H. Kantarjian, Michael J. Keating, Hagop M. Kantarjian and Hagop M. Kantarjian and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The American Journal of Medicine.

In The Last Decade

Jay Schachner

10 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jay Schachner United States 9 343 206 163 141 121 10 459
S Stass United States 10 247 0.7× 172 0.8× 160 1.0× 335 2.4× 215 1.8× 16 585
RT Silver United States 9 281 0.8× 141 0.7× 101 0.6× 344 2.4× 155 1.3× 13 580
B. Ceglarek Poland 9 379 1.1× 305 1.5× 145 0.9× 95 0.7× 41 0.3× 15 425
Michael J. Keating United States 8 222 0.6× 106 0.5× 57 0.3× 229 1.6× 161 1.3× 10 409
R. Vimercati Italy 11 192 0.6× 119 0.6× 66 0.4× 273 1.9× 56 0.5× 26 437
S Kotlarek-Haus Poland 6 303 0.9× 236 1.1× 152 0.9× 61 0.4× 37 0.3× 23 355
Moiseev Si Russia 4 393 1.1× 348 1.7× 181 1.1× 101 0.7× 29 0.2× 14 452
Monica Tozzi Italy 8 181 0.5× 139 0.7× 117 0.7× 139 1.0× 48 0.4× 16 366
Mt Fierro Italy 6 251 0.7× 165 0.8× 285 1.7× 65 0.5× 50 0.4× 11 428
Mary Browning United States 9 329 1.0× 322 1.6× 197 1.2× 94 0.7× 84 0.7× 17 461

Countries citing papers authored by Jay Schachner

Since Specialization
Citations

This map shows the geographic impact of Jay Schachner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Schachner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Schachner more than expected).

Fields of papers citing papers by Jay Schachner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Schachner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Schachner. The network helps show where Jay Schachner may publish in the future.

Co-authorship network of co-authors of Jay Schachner

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Schachner. A scholar is included among the top collaborators of Jay Schachner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Schachner. Jay Schachner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Lotzová, Eva, C. A. Savary, Klára Tótpál, et al.. (1991). Highly oncolytic adherent lymphocytes: Therapeutic relevance for leukemia. Leukemia Research. 15(4). 245–254. 14 indexed citations
2.
Kantarjian, Hagop M., Jay Schachner, & Michael J. Keating. (1991). Fludarabine therapy in hairy cell leukemia. Cancer. 67(5). 1291–1293. 48 indexed citations
3.
Keating, Michael J., H. Kantarjian, Charles Koller, et al.. (1991). Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.. Journal of Clinical Oncology. 9(1). 44–49. 206 indexed citations
5.
Kantarjian, Hagop M., Craig C. Childs, Susan O’Brien, et al.. (1991). Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. The American Journal of Medicine. 90(2). 223–228. 33 indexed citations
6.
Kantarjian, Hagop M., Craig C. Childs, Susan O’Brien, et al.. (1991). Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. The American Journal of Medicine. 90(1). 223–228. 45 indexed citations
7.
Keating, Michael J., Elihu H. Estey, Susan O’Brien, et al.. (1990). Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer. 65(1). 5–8. 38 indexed citations
8.
Shtalrid, M, Moshe Talpaz, Mark Blick, et al.. (1988). Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy.. Journal of Clinical Oncology. 6(10). 1569–1575. 38 indexed citations
9.
Schachner, Jay, Hagop M. Kantarjian, Willard T. Dalton, et al.. (1988). Cytogenetic association and prognostic significance of bone marrow blast cell terminal transferase in patients with acute myeloblastic leukemia.. PubMed. 2(10). 667–71. 17 indexed citations
10.
Schachner, Jay, Mark Blick, Emil J. Freireich, Jordan U. Gutterman, & Miloslav Beran. (1988). Suppression of c-myc and c-myb expression in myeloid cell lines treated with recombinant tumor necrosis factor-alpha.. PubMed. 2(11). 749–53. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026